Investing in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago would have delivered you a 38% gain
The main point of investing for the long term is to make money. But more than that, you probably want to see it ...
A number of research analysts recently issued reports on FENC shares. Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results